Literature DB >> 8158220

LDL-apheresis cannot be recommended for treatment of cerebrotendinous xanthomatosis.

V M Berginer, G Salen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8158220     DOI： 10.1016/0022-510x(94)90357-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


× No keyword cloud information.
  2 in total

1.  Nationwide survey on cerebrotendinous xanthomatosis in Japan.

Authors:  Yoshiki Sekijima; Shingo Koyama; Tsuneaki Yoshinaga; Masayoshi Koinuma; Yuji Inaba
Journal:  J Hum Genet       Date:  2018-01-10       Impact factor: 3.172

2.  Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

Authors:  Shingo Koyama; Yoshiki Sekijima; Masatsune Ogura; Mika Hori; Kota Matsuki; Takashi Miida; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-08       Impact factor: 4.928
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.